Drug Trial Radar · NCT02899000
A Treatment for Severe Inflammatory Acne Subjects
Last checked: Nov 20, 2026Latest source record: Dec 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
186
Actual
Start
Jul 29, 2016
Primary completion
Mar 28, 2017
Study completion Jun 27, 2017
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Sep 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules or cysts (non-nodulocystic) during a 12-week treatment period.
Conditions
- Acne Vulgaris
Interventions
Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gelDrug
Topical acne therapy
Oral doxycycline hyclateDrug
Tetracycline-class oral antibacterial 200 mg daily (2 tablets \[50 mg\], twice daily)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Number of Inflammatory LesionsTime frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Galderma Laboratories, LP
Fort Worth, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.